IQVIA (IQV) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does IQVIA (IQV) do?
IQVIA Holdings Inc (IQV) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Runs outsourced clinical trials and laboratory testing for drug developers worldwide. The business links global patient prescription data with outsourced clinical trial operations for pharmaceutical. It is worth $41.29B on the market and sold $17.35B over the last year.
- Market cap
- $41.29B
- P/E ratio
- 30.4×
- Annual sales
- $17.35B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 15, 2026
Brands and businesses behind IQV
- Q2 Solutions: Provides central laboratory services and bioanalytical testing for clinical trials under long-term research contracts.
- MIDAS: Licenses global prescription sales and pricing data to pharmaceutical companies through recurring subscriptions.
- PharMetrics Plus: Provides longitudinal patient claims data subscriptions to healthcare researchers and pharmaceutical manufacturers.
IQV’s flags, in plain English
Each flag is a number from IQVIA’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Earns Its Keep
Earns 21.8% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Cheap on Cash Flow
Priced at 19.9 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Debt Is Driving
Heavy debt, 245% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about IQV
How big is IQVIA?
IQVIA’s market cap is $41.29B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $17.35B: what customers paid the company over the last year, before any costs.
What is IQV’s P/E ratio?
IQV’s P/E ratio is 30.4×. Investors pay about 30.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with IQV?
High interest rates pressure funding for small biotechnology clients that make up a notable share of research contract sales. That is one risk on IQVIA’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From IQVIA’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IQV’s filings on SEC.gov. The Margin Monkey is research, not advice.
